middle.news
Percheron Therapeutics Cuts ATL1103, Limits ATL1102 Spend, Eyes New Rare Disease Assets
5:13am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Percheron Therapeutics Cuts ATL1103, Limits ATL1102 Spend, Eyes New Rare Disease Assets
5:13am on Monday 2nd of June, 2025 AEST
Key Points
Discontinuation of ATL1103 program and no further material investment in ATL1102
ATL1102 Phase IIb trial in Duchenne muscular dystrophy showed pharmacological activity but insufficient clinical efficacy
Active in-licensing discussions with non-binding term sheet submitted for a neurological rare disease asset
Significant cost containment measures including headcount reduction and executive pay deferrals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE